GERN Quote, Financials, Valuation and Earnings

Madrigal Pharmaceuticals has a net margin of -53.33% compared to Geron's net margin of -57.51%. Geron's return on equity of -59.29% beat Madrigal Pharmaceuticals's return on equity of -63.91%.

Geron has a consensus price target of $4.50, signalling upside risk potential of 246.15%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $414.07 which suggests that it could grow by 34.72%. Given that Geron has higher upside potential than Madrigal Pharmaceuticals, analysts believe Geron is more attractive than Madrigal Pharmaceuticals.

Geron has a beta of 0.661, which suggesting that the stock is 33.916% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.683, suggesting its less volatile than the S&P 500 by 168.299%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Geron quarterly revenues are $47.5M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $103.3M. Geron's net income of -$25.4M is higher than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, Geron's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 10.91x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -53.33% compared to Geron's net margin of -103.5%. Geron's return on equity of -59.29% beat Rhythm Pharmaceuticals's return on equity of -178.94%.

Geron has a consensus price target of $4.50, signalling upside risk potential of 246.15%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $79.25 which suggests that it could grow by 37.04%. Given that Geron has higher upside potential than Rhythm Pharmaceuticals, analysts believe Geron is more attractive than Rhythm Pharmaceuticals.

Geron has a beta of 0.661, which suggesting that the stock is 33.916% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.321, suggesting its more volatile than the S&P 500 by 132.096%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Geron quarterly revenues are $47.5M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $41.8M. Geron's net income of -$25.4M is higher than Rhythm Pharmaceuticals's net income of -$43.3M. Notably, Geron's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 10.91x versus 27.11x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Alpha Teknova has a net margin of -53.33% compared to Geron's net margin of -61.73%. Geron's return on equity of -59.29% beat Alpha Teknova's return on equity of -31.69%.

Geron has a consensus price target of $4.50, signalling upside risk potential of 246.15%. On the other hand Alpha Teknova has an analysts' consensus of $10.67 which suggests that it could grow by 103.33%. Given that Geron has higher upside potential than Alpha Teknova, analysts believe Geron is more attractive than Alpha Teknova.

Geron has a beta of 0.661, which suggesting that the stock is 33.916% less volatile than S&P 500. In comparison Alpha Teknova has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alpha Teknova offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Alpha Teknova pays out -- of its earnings as a dividend.

Geron quarterly revenues are $47.5M, which are larger than Alpha Teknova quarterly revenues of $9.3M. Geron's net income of -$25.4M is lower than Alpha Teknova's net income of -$5.7M. Notably, Geron's price-to-earnings ratio is -- while Alpha Teknova's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 10.91x versus 6.70x for Alpha Teknova. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -53.33% compared to Geron's net margin of -296.76%. Geron's return on equity of -59.29% beat Zevra Therapeutics's return on equity of -208.85%.

Geron has a consensus price target of $4.50, signalling upside risk potential of 246.15%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 229.65%. Given that Geron has higher upside potential than Zevra Therapeutics, analysts believe Geron is more attractive than Zevra Therapeutics.

Geron has a beta of 0.661, which suggesting that the stock is 33.916% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.938, suggesting its more volatile than the S&P 500 by 93.751%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Geron quarterly revenues are $47.5M, which are larger than Zevra Therapeutics quarterly revenues of $12M. Geron's net income of -$25.4M is higher than Zevra Therapeutics's net income of -$35.7M. Notably, Geron's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 10.91x versus 12.85x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.